We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
Read MoreHide Full Article
Editas Medicine, Inc. (EDIT - Free Report) announced that it has started enrollment in the first of two planned pediatric cohorts in the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness.
The company started enrollment in the above-mentioned study following the Independent Data Monitoring Committee’s (“IDMC”) endorsement to proceed with the first pediatric cohort.
The IDMC endorsement was based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts of the BRILLIANCE study, which is investigating EDIT-101 for treating LCA10. Dosing has been completed in the adult mid-dose cohort of the study.
Editas will now run the pediatric mid-dose cohort and the adult high-dose cohort concurrently, with first dosing expected this summer and dosing completion anticipated in the first half of 2022. Initial data from the same is expected in September of the ongoing year.
Shares of Editas were up 3.9% on Wednesday following the announcement of the aforementioned news. However, the stock has plunged 46.1% so far this year compared with the industry’s decrease of 1.1%.
Image Source: Zacks Investment Research
We note that Editas has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10. The disease has a significant unmet need as no therapy has been approved yet.
Notably, in August 2020, Editas terminated its 2017 agreement with Allergan [now part of AbbVie (ABBV - Free Report) ] and regained the full global rights to develop, manufacture and commercialize its ocular medicines, including EDIT-101.
If successfully developed and upon potential approval, EDIT-101 will be a boost for the company’s growth prospects as it will be able to generate revenues.
Editas has no approved product in its portfolio at the moment. Therefore, pipeline development remains a key focus for the company. However, stiff competition is a headwind for Editas, as other companies like Intellia Therapeutics (NTLA - Free Report) and CRISPR Therapeutics (CRSP - Free Report) are also engaged in developing candidates to address different indications using CRISPR/Cas9 gene-editing technology.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
Editas Medicine, Inc. (EDIT - Free Report) announced that it has started enrollment in the first of two planned pediatric cohorts in the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness.
The company started enrollment in the above-mentioned study following the Independent Data Monitoring Committee’s (“IDMC”) endorsement to proceed with the first pediatric cohort.
The IDMC endorsement was based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts of the BRILLIANCE study, which is investigating EDIT-101 for treating LCA10. Dosing has been completed in the adult mid-dose cohort of the study.
Editas will now run the pediatric mid-dose cohort and the adult high-dose cohort concurrently, with first dosing expected this summer and dosing completion anticipated in the first half of 2022. Initial data from the same is expected in September of the ongoing year.
Shares of Editas were up 3.9% on Wednesday following the announcement of the aforementioned news. However, the stock has plunged 46.1% so far this year compared with the industry’s decrease of 1.1%.
We note that Editas has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10. The disease has a significant unmet need as no therapy has been approved yet.
Notably, in August 2020, Editas terminated its 2017 agreement with Allergan [now part of AbbVie (ABBV - Free Report) ] and regained the full global rights to develop, manufacture and commercialize its ocular medicines, including EDIT-101.
If successfully developed and upon potential approval, EDIT-101 will be a boost for the company’s growth prospects as it will be able to generate revenues.
Editas has no approved product in its portfolio at the moment. Therefore, pipeline development remains a key focus for the company. However, stiff competition is a headwind for Editas, as other companies like Intellia Therapeutics (NTLA - Free Report) and CRISPR Therapeutics (CRSP - Free Report) are also engaged in developing candidates to address different indications using CRISPR/Cas9 gene-editing technology.
Zacks Rank
Editas currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>